+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy



Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy



International Journal of Cardiology 248: 355-360



This study investigated the prevalence of atherogenic dyslipidemia (AD) in Chinese outpatients whose low-density lipoprotein cholesterol (LDL-C) levels reached the goals with statin monotherapy and evaluated the characteristics of these patients. An analysis of the Dyslipidemia International Survey-China study that was carried out at 122 hospitals in China. Among patients reaching their LDL-C goals, the presence of AD was defined as triglyceride levels ≥1.7mmol/L and/or low levels of high-density lipoprotein cholesterol (men: <1.0mmol/L; women: <1.3mmol/L). 22,039 patients receiving statin monotherapy were analyzed. According to the American National Cholesterol Education Program Adult Treatment Panel III, 13,088 patients reached LDL-C goals, and 7134 patients of them had AD. Age, male gender, BMI, sedentary lifestyle, diabetes mellitus, ischemic cerebrovascular disease, serum uric acid levels, and fasting plasma glucose (all P<0.05) were independently associated with AD. Based on the Chinese guideline for the management of dyslipidemia, 13,551 patients reached LDL-C goals, and 7719 patients of them had AD. Age, male gender, BMI, sedentary lifestyle, coronary heart disease, serum uric acid levels, and fasting plasma glucose (all P<0.05) were independently associated with AD. The intensity of statin therapy did not affect the prevalence of AD. There was a high prevalence of AD in Chinese patients with optimal statin treatment. Some risk factors associated with AD were identified, but these factors were slightly different according to two criteria/guidelines. The intensity of statin therapy did not reduce the prevalence of AD. A combination lipid therapy may be more suitable for Chinese patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060210213

Download citation: RISBibTeXText

PMID: 28689987

DOI: 10.1016/j.ijcard.2017.06.105


Related references

What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin. Vnitrni Lekarstvi 61(11): 971-975, 2015

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45(5): 1429-1436, 2014

Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy. Clinica e Investigacion en Arteriosclerosis 28(2): 87-93, 2017

Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?. Preventive Cardiology 10(1): 31-35, 2007

Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Current Medical Research and Opinion 26(12): 2833-2839, 2010

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy. American Journal of Cardiology 104(12): 1695-1696, 2009

Prevalence of atherogenic dyslipidemia: association with risk factors and cardiovascular risk in Spanish working population. "ICARIA" study. Atherosclerosis 235(2): 562-569, 2014

Atherogenic dyslipidemia and cardiovascular risk factors in obese children. International Journal of Endocrinology 2015: 912047, 2015

Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal 68(5): 646-654, 2016

The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia. Cardiovascular Therapeutics 33(5): 270-274, 2015

Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in Nigeria. Annals of African Medicine 15(4): 194-199, 2017

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. Vascular Health and Risk Management 10: 225-235, 2014

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27(5): 1067-1078, 2011

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia. Journal of Lipid Research 57(11): 2073-2087, 2016